In patients who switched from IV to SC C1INH LTP (n=48), the mean time-normalized number of HAE attacks (AAR; primary endpoint) was reduced by 12.3 from 15 attacks per year at baseline to 2.7 attacks per year during the C1INH SC treatment period (Figure 1A). The gene discussed is SERPING1; the disease is hereditary angioedema.